Bayer Said to Explore Sale of $1.1 Billion Dermatology BusinessBy , , and
German drugmaker working with JPMorgan on potential disposal
Bayer considering sale as it pursues Monsanto acquisition
Bayer AG is exploring the sale of its dermatology business, according to people familiar with the matter, as the German drugmaker gets rid of peripheral enterprises and pursues the takeover of crop chemicals rival Monsanto Co.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.